Ποια είναι η τιμή για Glenmark Life Sciences Limited (GLS)

Η τιμή για Glenmark Life Sciences Limited (GLS) είναι $12.18

Ποια είναι η κεφαλαιοποίηση αγοράς για Glenmark Life Sciences Limited (GLS)

Η κεφαλαιοποίηση αγοράς για Glenmark Life Sciences Limited (GLS) είναι $1.49B

Glenmark Life Sciences Limited (GLS) Τιμή και Κεφαλαιοποίηση Αγοράς

Glenmark Life Sciences Limited, an Indian entity established in Mumbai in 2011, specializes in the creation, manufacturing, and distribution of high-value active pharmaceutical ingredients (APIs). These APIs are utilized across a wide array of chronic therapeutic areas. The company's diverse portfolio includes compounds for managing cardiovascular diseases (e.g., Olmesartan, Rosuvastatin, Amiodarone), central nervous system conditions (such as Oxcarbazepine, Topiramate, Lacosamide), and diabetes (including Glimepiride, Teneligliptin, Linagliptin). Additionally, they produce APIs for pain management (Etoricoxib, Lornoxicam), gastro-intestinal disorders, anti-infective treatments, respiratory ailments, and anti-emetic applications, featuring products like Atovaquone, Fluconazole, and Esomeprazole Magnesium. Beyond API production, Glenmark Life Sciences offers contract development and manufacturing (CDMO) solutions to numerous multinational and specialty pharmaceutical firms. Operating as a subsidiary of Glenmark Pharmaceuticals Limited, the company exports its products worldwide, reaching markets in Europe, North America, Latin America, and Japan.

Η τιμή για GLS	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$45,145.84 $1.49B	NVDA	$5.532T	+370,425.69%
$37,609.27 $1.49B	AAPL	$4.608T	+308,570.80%
$33,426.25 $1.49B	GOOG	$4.096T	+274,239.49%
$30,592.54 $1.49B	MSFT	$3.748T	+250,982.34%
$22,536.64 $1.49B	AMZN	$2.761T	+184,865.08%

Η τιμή για GLS

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$45,145.84 $1.49B